Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer
Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer have?
Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer has 2,398 citations in the OpenAlex counts ScholarIQ stores.
When was Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer published?
Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer has 2011 year in the ScholarIQ index.
What is the open-access status of Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer?
Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer has bronze oa status in the ScholarIQ index.
What is the DOI of Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer?
The DOI for Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer is on the source record.
What is the PMID of Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer?
The PMID for Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer is on the source record.
What is the OpenAlex record for Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer?
The OpenAlex for Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer is on the source record.